Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Impact of treatment-related adverse events on efficacy of intralesional collagenase therapy for Peyronie’s disease

International Journal of Impotence Research volume 33, pages 128–130 (2021)Cite this article

Subjects

Men affected by Peyronie’s disease (PD) develop plaques within the penile tunica albuginea. Sequelae of plaque formation include pain, curvature, hourglassing, loss of size, and erectile dysfunction [1, 2]. The only medical therapy federally approved in the United States for treatment of PD is intralesional collagenase, which is administered as a series of injections [3].

The safety and efficacy of collagenase were evaluated in two randomized, phase 3 clinical trials (IMPRESS I & II) [4]. IMPRESS showed significant improvements in penile curvature with collagenase compared to placebo (34% vs. 18.2% improvement; p < 0.0001), with the most common treatment-related adverse events (TRAEs) being ecchymosis, pain, and swelling. No study to date has examined the impact of TRAEs on the ultimate efficacy of intralesional collagenase for PD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Smith JF, Walsh TJ, Conti SL, Turek P, Lue T. Risk factors for emotional and relationship problems in Peyronie’s disease. J Sex Med. 2008;5:2179–84.

    Article  Google Scholar 

  2. Taylor FL, Levine LA. Peyronie’s Disease. Urol Clin N Am. 2007;34:517–34.

    Article  Google Scholar 

  3. Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116:650–6.

    Article  CAS  Google Scholar 

  4. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

    Article  CAS  Google Scholar 

  5. Amighi A, Mills SA, Eleswarapu SV, Regets KV, Mendhiratta N, Mills JN. A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie’s disease results in reduced procedural morbidity using a standardized hematoma classification rubric. World J Urol. 2020;38:293–8.

    Article  Google Scholar 

Download references

Acknowledgements

SVE is funded by a Research Scholar Award from the American Urological Association and Urology Care Foundation. The funding organizations played no part in the conduct of this study.

Author information

Authors and Affiliations

  1. Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Dyvon T. Walker, Robert H. Shahinyan, Arash Amighi, Keith V. Regets, Jesse N. Mills & Sriram V. Eleswarapu

Authors
  1. Dyvon T. Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert H. Shahinyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arash Amighi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keith V. Regets
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jesse N. Mills
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sriram V. Eleswarapu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sriram V. Eleswarapu.

Ethics declarations

Conflict of interest

SVE serves as a consultant to Metuchen Pharmaceuticals and receives compensation. JNM serves as a consultant to Antares Pharma, Boston Scientific Corporation, and Endo Pharmaceuticals and receives compensation. DTW, RHS, AA, and KVR declare no potential conflicts of interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walker, D.T., Shahinyan, R.H., Amighi, A. et al. Impact of treatment-related adverse events on efficacy of intralesional collagenase therapy for Peyronie’s disease. Int J Impot Res 33, 128–130 (2021). https://doi.org/10.1038/s41443-020-0311-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41443-020-0311-z

Search

Advanced search

Quick links